Mutual Fund Details
NAV
₹33.9437
as on 13 Nov 2024, 11:17 PM
₹-0.4643(1.35%)
Last Change
Scheme Ratings
4
rated by Value Research
Pharma
Rankings based on | as on Invalid date
×
Schemes Managed By
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,69,933
₹1,77,662
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹77,662
Profit (absolute return)
77.66%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 3 months
0.37%
In the last 6 months
17.76%
In the last 1 year
43.85%
In the last 3 years
77.66%
In the last 5 years
256.60%
In the last 10 years
NA
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
Tata India Pharma & HealthCare Fund Direct-Growth
as of 31 Oct 2024, 05:30 AM
₹1,208.05 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 0.25% if redeemed within 30 days.
0.69%
Expense Ratio
Plan
Growth
Benchmark
NIFTY Pharma Total Return Index
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Scheme Document
Sectors Holding in this Mutual Fund
as on 31 Oct 2024
Healthcare
90.20%
₹1,089.66 Cr
Cash Holding
5.39%
₹65.11 Cr
Services
2.29%
₹27.66 Cr
Chemicals
1.26%
₹15.22 Cr
Others
0.86%
₹10.39 Cr
Companies Holding in this Mutual Fund
as on 31 Oct 2024
Sun Pharmaceutical Industries Ltd.
12.89%
₹155.72 Cr
Aurobindo Pharma Ltd.
9.43%
₹113.92 Cr
Lupin Ltd.
8.72%
₹105.34 Cr
Dr. Reddy's Laboratories Ltd.
7.26%
₹87.70 Cr
Cipla Ltd.
6.48%
₹78.28 Cr
Others
55.22%
₹667.08 Cr
View All
View All
This fund's returns:
21.07%Return Duration
3 Years
SBI Healthcare Opportunities Fund Direct Plan-Growth
EquityPharma
Min. Investment
₹500
Category Returns
15.81%
23.95%
3Y Returns
23.95
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.81%
23.95%
3Y Returns
23.28
DSP Healthcare Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.81%
23.95%
3Y Returns
22.68
About Tata India Pharma & HealthCare Fund Direct-Growth
Tata India Pharma & HealthCare Fund Direct-Growth is a Equity mutual fund scheme from Tata Mutual Fund. This scheme was launched on Invalid date and is currently managed by its fund manager Meeta Shetty. It has an AUM of ₹1,208.05 Crores and the latest NAV decalared is ₹33.944 as on 14 Nov 2024 at 9:55 pm.
Tata India Pharma & HealthCare Fund Direct-Growth scheme return performance in last 1 year is 43.85%, in last 3 years is 77.66% and 238.25% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹1,208.05 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Tata Mutual Fund
View AMC Details
₹1,84,446.31 Cr
AUM
158
Schemes
Address
9th Floor, Mafatlal Centre,Nariman Point,400021
Phone Number
Phone : 1800-209-0101
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
